Bristol Myers Squibb to Present Data at on CAMZYOS (mavacamt

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.

Related Keywords

Georgia , United States , Atlanta , Roland Chen , Global Drug Development For Bristol Myers Squibb , American College Of Cardiology , Neuroscience Development , Bristol Myers Squibb , American College , Scientific Session , Senior Vice President , Global Drug Development , Bristol Myers , Risk Evaluation , Mitigation Strategy ,